Xichen Lin - 01 Mar 2025 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Reporting relationship: CHIEF SCIENTIFIC OFFICER
Issuer ticker: GPCR
Reported as of: 01 Mar 2025
Net transaction value: -$50,991
SEC form: 4
Accepted by SEC: 03 Jul 2025, 17:15:09 UTC
Prior SEC filing: 05 Jun 2024
Next SEC filing: 18 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Jun Yoon, Attorney-in-Fact

Key filing fact

Xichen Lin filed Form 4 for Structure Therapeutics Inc. (GPCR) on 03 Jul 2025.

Key facts

This page summarizes Xichen Lin's Form 4 filing for Structure Therapeutics Inc. (GPCR).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Jul 2025, 17:15.

Change

Previous filing in this sequence was filed on 05 Jun 2024.
Current net transaction value: -$50,991.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001962926 Primary reporting owner

Lin Xichen

Relationship: CHIEF SCIENTIFIC OFFICER
Address: C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO
Signature: /s/ Jun Yoon, Attorney-in-Fact
Signature date: 03 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GPCR transaction

Ordinary Shares

Tax liability

Transaction value: $50,991
Shares: -6,441
Change %: -3.9%
Price: $7.92
Shares after: 160,095
Date: 01 Mar 2025
Ownership: Direct
Footnotes: F1, F2

GPCR transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +57,078
Change %: +36%
Price: $0.000000
Shares after: 217,173
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

Footnote F2

Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

Footnote F3

On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.